Cetuximab-induced aseptic meningitis

Ann Oncol. 2009 Sep;20(9):1609-1610. doi: 10.1093/annonc/mdp382. Epub 2009 Jul 30.

Authors

T M Feinstein¹, M K Gibson¹, A Argiris²

Affiliations

¹ Head and Neck Cancer Program, University of Pittsburgh Cancer Institute and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
² Head and Neck Cancer Program, University of Pittsburgh Cancer Institute and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: argirisae@upmc.edu.

PMID: 19643807
DOI: 10.1093/annonc/mdp382

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Allergic Agents / administration & dosage
Anti-Inflammatory Agents / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Carcinoma, Squamous Cell / drug therapy*
Cetuximab
Dexamethasone / administration & dosage
Diphenhydramine / administration & dosage
Humans
Laryngeal Neoplasms / drug therapy
Male
Meningitis, Aseptic / chemically induced*
Middle Aged
Premedication
Tonsillar Neoplasms / drug therapy

Substances

Anti-Allergic Agents
Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Dexamethasone
Diphenhydramine
Cetuximab